SUZHOU, China, June 9, 2025 /PRNewswire/ -- Neowise Biotechnology ("Neowise"), a pioneering company focused on the development of TCR-T cell therapies for solid tumors, announced today that it has entered into a non-exclusive licensing agreement with BeOne Medicines Ltd. ("BeOne"). Under the terms of the agreement, Neowise will grant BeOne rights...